HOUSE-BILL 3789: H.R.3789 - DTC Act of 2025
AI-Powered Summary
HOUSE-BILL 3789 aims to enhance transparency in the pricing of prescription drugs and biological products by mandating that direct-to-consumer advertisements include pricing information. This legislation addresses major themes of consumer empowerment and healthcare affordability, allowing individuals to make informed decisions about their healthcare options. Key provisions include the requirement for pricing disclosure in advertisements, with exemptions for drugs priced below $35, which may limit its effectiveness on lower-cost medications. The bill also raises constitutional considerations regarding the regulation of commercial speech under the First Amendment and potential due process issues under the Fifth Amendment due to penalties for non-compliance. Implementation will be overseen by the Secretary of Health and Human Services, who will establish regulations to ensure compliance. The potential impacts include increased competition in the pharmaceutical market, leading to lower prices for consumers and improved financial planning in healthcare choices.
Demographic Impact Analysis
Summary
Overall Constitutional Implications
The bill enhances individual rights by promoting transparency in healthcare, which is essential for informed consumer choices. It aims to empower individuals across various demographic groups by providing critical information about drug pricing, potentially leading to better healthcare access and affordability.
Key Individual Rights
- Right to Information (First Amendment)
- Equal Protection under the Law (Fourteenth Amendment)
Constitutional Provisions
- First Amendment
- Fourteenth Amendment
- Commerce Clause
Potential Constitutional Challenges Or Support
While the bill supports transparency and consumer rights, there are concerns about its implementation potentially leading to unequal access to information, particularly for marginalized groups. Additionally, the regulation of commercial speech may face scrutiny regarding its impact on pharmaceutical pricing strategies.
Summary
HOUSE-BILL 3789 has the potential to significantly impact individuals across various demographic categories by enhancing transparency in pharmaceutical pricing. By mandating clear pricing information, the bill seeks to empower consumers, particularly those from lower-income backgrounds or marginalized communities, thereby addressing disparities in healthcare access. However, careful implementation is necessary to avoid unintended consequences that could undermine its benefits.
Constitutional Analysis
This bill appears to align with constitutional principles. The proposed legislation operates within the established framework of constitutional authority and does not appear to conflict with fundamental rights or the separation of powers.
Analysis generated using AI-powered review of constitutional principles and legal precedents.
Take Action
Text 50409
💡 How to use:
These links will start a conversation with ResistBot. When prompted, mention H.R. 3789 to reference this bill.
Contact Your Representatives
Write to YOUR elected officials about this bill
Rate This Bill
Sign in to save a private rating for this bill and track your civic engagement over time.
Sign In FreePolicy Topics
Timeline
June 5, 2025
Bill Introduced
Current
Referred to Committee
June 12, 2026
Last Updated
Ask the Constitutional AI About This Bill
Sign in free to chat with our constitutional analysis AI about this bill — get plain-English explanations, constitutional concerns, and demographic impact estimates personalized to you.
Sign In Free to Chat